Refractory Multiple Myeloma, Stage III Multiple Myeloma, Stage II Multiple Myeloma, Stage I Multiple Myeloma
Conditions
Brief summary
This phase II trial studies the side effects and how well giving thalidomide, dexamethasone, and clarithromycin together works in treating patients with multiple myeloma previously treated with transplant. Biological therapies, such as thalidomide and clarithromycin, may stimulate the immune system in different ways and stop cancer cells from growing. Dexamethasone also works in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving thalidomide together with dexamethasone and clarithromycin after a transplant may be an effective treatment for multiple myeloma
Detailed description
OBJECTIVES: I. Evaluate the toxicity of the use of Thalidomide/Biaxin (Clarithromycin)/Dexamethasone as maintenance therapy after autologous/syngeneic transplant. II. Evaluate the median time to disease progression. III. Evaluate survival. OUTLINE: Patients receive thalidomide orally (PO) once daily (QD), dexamethasone PO once weekly, and clarithromycin PO twice daily (BID). Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Treatment with thalidomide continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically.
Interventions
DRUGclarithromycin
Given PO
DRUGthalidomide
Given PO
DRUGdexamethasone
Given PO
Sponsors
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Any autologous or syngeneic patient who underwent high dose melphalan (\>= 140 mg/m\^2) therapy/peripheral blood stem cell (PBSC) or bone marrow (BM) rescue for any stage of multiple myeloma and did not participate in another clinical transplant trial which is also evaluating disease free survival or survival * Platelet count (transfusion independent) \> 50,000 cells/mm\^3 for 5 calendar days after recovery from high dose * Absolute granulocyte count \> 1500 cells/mm\^3 for 5 calendar days after recovery from high dose * Patients will start therapy between 30 days to 120 days after transplant * Willingness and ability to comply with Food and Drug Administration (FDA)-mandated S.T.E.P.S. (Celgene System for Thalidomide Education and Prescribing Safety) Program * Signing a written informed consent form
Exclusion criteria
* Karnofsky score less than 70 * A left ventricular ejection fraction less than 45%; patients with congestive heart disease, history of myocardial infarction (MI), or coronary artery disease * Total bilirubin greater than 2 mg/ml (unless history of Gilbert's disease) * Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) \> 2.5 x upper limit of normal * History of deep venous thrombus, arterial occlusions, or pulmonary emboli * Pregnant and/or lactating females * Patients who cannot give informed consent * Patients with untreated systemic infection * Patients with history prior to transplant of treatment with combination therapy Thalidomide/Biaxin and Steroid without response * Patients allergic to Thalidomide, Biaxin or Dexamethasone * Referring physician not registered with S.T.E.P.S. program or unwilling to oversee the care of the patients on study and comply with the FDA-mandated S.T.E.P.S. Program * Patients unwilling to practice adequate forms of contraception if clinically indicated; male patients on study need to be consulted to use latex condoms even if they have had a vasectomy every time they have sex with a woman who is able to have children while they are being treated and for four weeks after stopping drugs * Patients with history of seizures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Toxicity of proposed treatment with clarithromycin, dexamethasone, and thalidomide | First 3 months of therapy |
Secondary
| Measure | Time frame |
|---|---|
| Time to disease progression | Up to 15 years |
Countries
United States
Outcome results
None listed